Publications by authors named "Theodore E Spiro"

Claim this Profile
E
Extended Thromboprophylaxis in Hospitalized Patients with Heart Failure: A Post Hoc Analysis of the MAGELLAN Study.
Alex C Spyropoulos, Gary E Raskob, Theodore E Spiro, Wentao Lu, Yoriko De Sanctis

TH Open· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial.
Alex C Spyropoulos, Mark Goldin, Walter Ageno, Gregory W Albers, C Gregory Elliott, Theodore E Spiro

TH Open· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials.
Alex C Spyropoulos, Gary E Raskob, Alexander T Cohen, Walter Ageno, Jeffrey I Weitz, Theodore E Spiro

Circulation· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER.
Gary E Raskob, Alex C Spyropoulos, Theodore E Spiro, Wentao Lu, Zhong Yuan

J Am Heart Assoc· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients.
Gary E Raskob, Alex C Spyropoulos, Alexander T Cohen, Jeffrey I Weitz, Walter Ageno, Theodore E Spiro

J Am Heart Assoc· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism.
Isabel Reinecke, Alexander Solms, Stefan Willmann, Theodore E Spiro, Gary Peters

J Thromb Thrombolysis· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism.
Alexander Solms, Stefan Willmann, Isabel Reinecke, Theodore E Spiro, Gary Peters

J Thromb Thrombolysis· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients.
Alex C Spyropoulos, Walter Ageno, Gregory W Albers, C Gregory Elliott, Jonathan L Halperin, Theodore E Spiro

J Am Coll Cardiol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial: Insights From COMMANDER HF.
Jonathan W Cunningham, João Pedro Ferreira, Hsiaowei Deng, Stefan D Anker, William M Byra, Theodore E Spiro

JACC Heart Fail· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study.
Alex C Spyropoulos, Concetta Lipardi, Jianfeng Xu, Wentao Lu, Eunyoung Suh, Theodore E Spiro

Clin Appl Thromb Hemost· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
Jeffrey I Weitz, Gary E Raskob, Alex C Spyropoulos, Theodore E Spiro, Yoriko De Sanctis

Thromb Haemost· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis.
Alex C Spyropoulos, Concetta Lipardi, Jianfeng Xu, Colleen Peluso, Theodore E Spiro

TH Open· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling.
Alexander Solms, Matthias Frede, Scott D Berkowitz, Anne Hermanowski-Vosatka, Dagmar Kubitza, Theodore E Spiro

CPT Pharmacometrics Syst Pharmacol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial.
Mandeep R Mehra, Muthiah Vaduganathan, Min Fu, João Pedro Ferreira, Stefan D Anker, Theodore E Spiro

Eur Heart J· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Barry Greenberg, James D Neaton, Stefan D Anker, William M Byra, John G F Cleland, Theodore E Spiro

JAMA Cardiol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.
Faiez Zannad, Stefan D Anker, William M Byra, John G F Cleland, Min Fu, Theodore E Spiro

N Engl J Med· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.
Alex C Spyropoulos, Walter Ageno, Gregory W Albers, C Gregory Elliott, Jonathan L Halperin, Theodore E Spiro

N Engl J Med· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.
Alexandre Mebazaa, Theodore E Spiro, Harry R Büller, Lloyd Haskell, Dayi Hu

Circulation· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Laboratory assessment of rivaroxaban: a review.
Meyer Michel Samama, Geneviève Contant, Theodore E Spiro, Elisabeth Perzborn, Lena Le Flem

Thromb J· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Alexander T Cohen, Theodore E Spiro, Alex C Spyropoulos,

N Engl J Med· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Alexander T Cohen, Theodore E Spiro, Harry R Büller, Lloyd Haskell, Dayi Hu

N Engl J Med· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial.
Meyer Michel Samama, Genevieve Contant, Theodore E Spiro, Elisabeth Perzborn, Lena Le Flem

Clin Appl Thromb Hemost· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls.
Meyer Michel Samama, Genevieve Contant, Theodore E Spiro, Elisabeth Perzborn, Céline Guinet

Thromb Haemost· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol.
Alexander Thomas Cohen, Theodore Erich Spiro, Harry Roger Büller, Lloyd Haskell, Dayi Hu

J Thromb Thrombolysis· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assays for measuring rivaroxaban: their suitability and limitations.
Edelgard Lindhoff-Last, Meyer Michel Samama, Thomas L Ortel, Jeffrey I Weitz, Theodore E Spiro

Ther Drug Monit· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis